0 Canadian Stock Exchange News - November 29, 2018MGX Minerals Announces Mobilization for Drilling at Francisco Basin Lithium Project, ChileVANCOUVER, British Columbia, Nov. 29, 2018 (GLOBE NEWSWIRE) — MGX Minerals Inc. (“MGX” or the “Company”) (CSE: XMG / FKT: […]Read More
0 NASDAQ Companies - November 29, 2018Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint InhibitorsLONDON, Nov. 29, 2018 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) entered into four collaboration agreements to […]Read More
0 NASDAQ Companies - November 29, 2018Opera Limited (OPRA) to Present at Upcoming Investor ConferencesOSLO, Norway, Nov. 29, 2018 (GLOBE NEWSWIRE) — Opera Limited (NASDAQ: OPRA), one of the world’s leading browser providers and […]Read More
0 TSX Venture News - November 29, 2018BTL™ Joins CitizenOS Project With Xinova and Helix Applications Inc.VANCOUVER, British Columbia and LONDON, Nov. 29, 2018 (GLOBE NEWSWIRE) — BTL GROUP LTD. (TSX Venture: BTL) (“BTL” or the […]Read More
0 TSX Venture News - November 29, 2018Helix Joins CitizenOS Project With Xinova and BTL GroupCALGARY, Alberta, Nov. 29, 2018 (GLOBE NEWSWIRE) — Helix Applications Inc. (TSX-V: HELX) (the “Company” or “Helix”) announces that it […]Read More
0 NASDAQ Companies - November 29, 2018TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology ProgramsI-Mab’s Broad and Innovative Pipeline to Leverage TRACON’s U.S. Product Development Solution Platform SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) […]Read More
0 NASDAQ Companies - November 29, 2018ObsEva SA to Host R&D Investor Day December 7, 2018Geneva, Switzerland and Boston, MA – November 29, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical […]Read More
0 NYSE Companies - November 29, 2018Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in EuropeApproval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% […]Read More
0 TSX Venture News - November 29, 2018Wow Unlimited Media Announces Financial Results for the Third Quarter of 2018VANCOUVER, British Columbia, Nov. 29, 2018 (GLOBE NEWSWIRE) — Wow Unlimited Media Inc. (“Wow” or the “Company”) (TSX-V: WOW; OTCQX: […]Read More